Claims
- 1. A therapeutic method for treatment of lesions of the body surface which comprises transplantation on said lesions of an artificial skin composed of a biocompatible support membrane consisting of materials of natural, synthetic or semisynthetic origin, and having a thickness of between 10 and 500 .mu.m, which contains an ordered series of holes of a defined and constant size between 10 and 1000 .mu.m, separated from each other by a constant distance of between 50 and 1000 .mu.m, together with autologous or heterologous epithelial cells in the active proliferation stage present within said holes and on both sides of said membrane.
- 2. The therapeutic method as claimed in claim 1, in which the epithelial cells are keratinocyte microcolonies.
- 3. The therapeutic method as claimed in claim 1, comprising shaping said artificial skin on the basis of the area to be treated and suturing it to said area.
- 4. The therapeutic method as claimed in claim 1, in which the holes size is between 40 and 70 .mu.m.
- 5. The therapeutic method as claimed in claim 1, in which the distance between holes is 80 .mu.m.
- 6. The therapeutic method as claimed in claim 1, in which membranes have a thickness comprised between 20 and 40 .mu.m.
- 7. The therapeutic method as claimed in claim 1, in which the biocompatible material of natural origin is selected from the group consisting of collagen, coprecipitates of collagen and glycosaminoglycans, cellulose, gelled polysaccharides, and natural rubbers, either alone or in mixture with each other or with polymers of synthetic or semisynthetic origin, in the presence of precipitating or gelling agents.
- 8. The therapeutic method as claimed in claim 7 in which the gelled polysaccharides are selected from the group consisting of chitin, chitosan, pectins or pectic acids, agar, agarose, xanthan gum, gellano, alginic acid or alginates, polymannans or polyglucans and starches.
- 9. The therapeutic method as claimed in claim 1, in which the biocompatible material of synthetic origin is chosen from the group consisting of polylactic acid, polyglycolic acid or copolymers thereof or their derivatives, polydioxanones, polyphosphazenes, polysulphones and polyurethanes.
- 10. The therapeutic method as claimed in claim 1, in which the biocompatible material of semisynthetic origin is chosen from the group consisting of semisynthetic derivatives of natural polymers crosslinked with crosslinking agents and derivatives of cellulose, of alginic acid, of starch, of hyaluronic acid, of chitin or chitosan, of gellano, of xanthan, of pectins or pectic acids, of polyglucans, of polymannans, of agar, of agarose, of natural rubbers or of glycosaminoglycans.
- 11. The therapeutic method as claimed in claim 10, in which the semysinthetic derivative of a natural polymer is collagen.
- 12. The therapeutic method as claimed in claim 10, in which the biocompatible membrane consists of hyaluronic acid benzyl ester with 100 percent of esterification.
- 13. The therapeutic method as claimed in claim 10, in which the crosslinking agent is selected from the group consisting of dialdehydes or their precursors, bicarboxylic acids or halides thereof and diamines.
- 14. The therapeutic method as claimed in claim 1, in which the materials of synthetic origin are selected from the group consisting of silicone, silane or siloxane rubbers, fluoropolymers, polystyrene, vinyl polychloride, polyacrylate or derivatives thereof, polyhydroxyacrylate, polyhydroxymethacrylate, carboxyvinyl polymers and their derivatives, maleic anhydride polymers and their derivatives, polyvinylchloride, polyvinylalchol and its derivatives, polyethylene and polypropylene.
- 15. The therapeutic method as claimed in claim 14, in which fluoropolymers are selected from the group consisting of polyfluoroethylene, polyfluoropropylene and polyfluoroethers.
- 16. The therapeutic method as claimed in claim 1, wherein the artificial skin is applied to the area to be treated on either of its two sides.
- 17. The therapeutic method as claimed in claim 1, wherein said artificial skin is cryopreserved.
Priority Claims (1)
Number |
Date |
Country |
Kind |
20513A90 |
Jun 1990 |
ITX |
|
Parent Case Info
This application is a divisional of copending application Ser. No. 08/209,626, filed on Mar. 14, 1994, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (3)
Foreign Referenced Citations (11)
Number |
Date |
Country |
0183184 |
Jun 1986 |
EPX |
0296078 |
Dec 1988 |
EPX |
0351016 |
Jan 1990 |
EPX |
0358506 |
Mar 1990 |
EPX |
2635966 |
Mar 1990 |
FRX |
3539270 |
May 1987 |
DEX |
2178447 |
Feb 1987 |
GBX |
8602273 |
Apr 1986 |
WOX |
8808305 |
Nov 1988 |
WOX |
8903228 |
Apr 1989 |
WOX |
9000595 |
Jan 1990 |
WOX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
209626 |
Mar 1994 |
|